Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 419

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 419
---
arrants at an exercise price of $400.00 per
warrant, (2) 110,675,600 Ordinary Shares represented 11,059 Depositary Shares issuable upon the exercise of the Series D Warrants at an
exercise price of $400.00 per warrant and, (3) 4,426,800 Ordinary Shares represented by 442 Depositary Shares issuable upon the exercise
of the May 2023 Placement Agent Warrants at an exercise price of $375.00 per warrant.

On
June 20, 2023 we issued the Series C warrants, Series D warrants and placement agent warrants to the investors and the placement agent
after receiving required shareholder approval of the allotment of, and disapplication of pre-emption rights with respect to the Ordinary
Shares to be issued under the Series C warrants, Series D warrants and placement agent warrants at our general meeting held on June 14,
2023.

On December 21, 2023, in two
private placement transactions, we issued (i) an aggregate of 8,997 Depositary Shares to certain secured noteholders in satisfaction of
the Adhera Therapeutics, Inc., and (y) an aggregate of 90,999 pre-funded warrants to purchase Depositary Shares to certain of the secured
noteholders, and (ii) issued to Melior Pharmaceuticals I, Inc. 14,177 of our Depositary Shares.

On February 26, 2024, in connection
with our Company’s obligations under a license agreement with Melior, we issued 14,177 Depositary Shares to Bukwang Pharmaceuticals
Co. Ltd.

On April 29, 2024, in connection
with the closing of a Emtora License Agreement, we issued 15,136 Depositary Shares to Emtora.

On May 24, 2024, in connection
with the transactions contemplated by the Warrant Agreements, we issued an aggregate of 124,181 Depositary Shares to certain holders of
our Series E Warrants and Series F Warrants, upon the exercise of 62,906 Series E Warrants and 61,275 Series F Warrants, at an exercise
price of $37.50 per share. In addition, we issued to such holders an aggregate of 94,358 Series G warrants, or the Series G Warrants,
and 147,805 Series H warrants, or the Series H Warrants. The aggregate gross proceeds to the Company were approximately $6.